Search Tag: terminal diseases

Immunicom Appoints Dr. Annette Marleau as Chief Technology Officer

2022 17 Feb

Dr. Marleau will direct the Company’s R&D efforts and advance its pipeline of subtractive therapies treating cancer and other terminal diseases Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies to treat unmet medical needs in cancer and other terminal diseases, announced that Dr. Annette Marleau is assuming... Read more

Communities

Women's Health Community Supported by Hologic

Comprehensive information on women’s health issues and management, management and personalisation.

Enterprise Imaging Community

Advanced and scalable radiology solutions that can help improve care coordination, increase speed and facilitate accurate clinical decisions.

Decision Support Community Supported by Siemens Healthineers

Leading the way in highlighting useful and efficient decision support tools for improved patient outcomes.

Sepsis Community Supported by Abionic

Addressing the latest developments in sepsis and providing clinically useful information for diagnosis and treatment of patients.

COVID-19 News

COVID-19 Associated with Higher Risk of Cardiovascular Disease

A study published in Cardiovascular Research found that COVID-19 is associated... Read more

What Do We Know About XBB.1.5?

The XBB.1.5 variant is a new sub-variant of Omicron. It has been identified... Read more

Major Healthcare Impacts of COVID-19

“Health at a Glance: Europe 2022” outlines the impact of the pandemic... Read more

JOIN OUR MANAGEMENT COMMUNITY

Choose subscription channel

Search Tag: terminal diseases

Immunicom Appoints Dr. Annette Marleau as Chief Technology Officer

Events Calendar